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1. Introduction 
Adenosine is a nucleoside distributed throughout the entire organism as an intermediary 
metabolite. At the extracellular level, adenosine plays multiple physiologic roles, interacting 
with specific receptors: A1, A2A, A2B and A3 (Fredholm et al., 2001). While the A1Rs and A3Rs 
are coupled in an inhibitory way to adenylate cyclase through the Gi/o protein, the A2Rs are 
coupled in a stimulatory way to this enzymatic activity through Gs protein (Ralevic & 
Burnstock, 1998).  
Adenosine levels are increased after ischemia, hypoxia, excitotoxicity, inflammation and 
cerebral lesions. In these situations, it is considered that high adenosine levels play a 
neuroprotective role (Ribeiro et al., 2002). Interestingly, adenosine regulates the release of 
glutamate, the main excitatory neurotransmitter of the nervous system (Sebastiao & Ribeiro, 
1996). A1Rs are widely expressed in the brain and have been shown to modulate neuronal 
excitability by decreasing pre-synaptic release of various neurotransmitters (Fredholm & 
Dunwiddie, 1988). The most dramatic inhibitory actions are on the glutamatergic system 
(Masino et al., 2002). In the central nervous system (CNS), A1Rs are associated with 
neuroprotective processes (Angulo et al., 2003; Dunwiddie and Masino, 2001). Moreover, 
they are upregulated in human neurodegenerative diseases with abnormal protein 
aggregates and it is related to compensatory mechanisms (Albasanz et al., 2007, 2008; 
Angulo et al., 2003; Perez-Buira et al., 2007; Rodríguez et al., 2006). Regarding A2ARs, these 
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receptors are concentrated in the striatum, modulating dopaminergic activity, but they are 
also present in the hippocampus and cerebral cortex, modulating the glutamate release in 
the brain. Adenosine activity through A2 receptors (A2ARs) can eventually give rise to 
neurotoxicity, neuronal damage and cellular death (de Mendoça et al., 2000). In fact, A2ARs 
activity is associated with the outcome of cerebral injury as well as the development of A-
induced synaptotoxicity (Canas et al., 2009; Cunha, 2005; Stone et al., 2009). 
2. Human brain A2AR localization and implications in PD pathophysiology 
As mentioned in the previous section, A2ARs are G protein-coupled receptors that stimulate 
adenylyl cyclase through Gs proteins, promoting accumulation of intracellular cAMP (Van 
Calker et al., 1979). The activation of these receptors mediates multiple physiological effects 
of adenosine, both in the CNS and in peripheral tissues (Fredholm et al., 2001). 
Pharmacological activation of A2ARs promotes vasodilatation, immunosuppression, tissue 
protection, sleep promotion and depression (Cerqueira, 2004; El Yacoubi et al., 2003; Linden, 
2001; Satoh et al., 1998).  
A2ARs are widely expressed, but they are highly concentrated in spleen, thymus, leukocytes 
and blood platelets. A2ARs levels in immune cells play a critical role in the protection of 
normal tissues by attenuating inflammation and tissue damage in vivo (Ohta and Sitkovsky, 
2001). In the CNS, A2ARs are highly expressed in the striatum (Peterfreund et al., 1996; 
Schiffmann et al., 1991). Most striatal neurons (95%) are GABAergic medium spiny neurons 
(MSNs) which can be divided into two subtypes. One subpopulation projects to the globus 
pallidus and contains enkephalin. The other subpopulation projects to the substantia nigra 
and contains substance P and dynorphin. These neurons receive inputs from glutamatergic 
afferents from cortical, thalamic and limbic areas and dopaminergic afferents from the 
substantia nigra pars compacta and the ventral tegmental area. MSNs promote two striatal 
efferent pathways, the “direct” and “indirect”, affecting motor activation and inhibition, 
respectively. The MSNs of the direct pathway correspond to the subpopulation containing 
dynorphin and they also express dopamine D1 receptors, whereas indirect MSNs express 
enkephalin, dopamine D2 receptors (D2Rs) and A2ARs (Schiffmann et al., 2007). In these cells, 
A2ARs physically interact (oligomerize) with D2R, and this receptor-receptor interaction 
results in a tidy adenosine/dopamine functional interaction controlled by the A2AR/D2R 
oligomer. Consequently, two reciprocal antagonistic A2AR/D2R interactions have been 
described, namely an intermembrane interaction in which A2AR mediates the inhibition of 
D2R, thus modulating neuronal excitability and neurotransmitter release, and an interaction 
at the level of adenylyl-cyclase in which D2R inhibits A2AR-mediated protein 
phosphorylation and gene expression (for review see Ciruela et al., 2011). As a result of this 
interaction, antagonists of A2ARs have recently emerged as a leading candidate class of non-
dopaminergic anti-parkinsonian agents, based in part on the unique CNS distribution of 
A2ARs and A2AR/D2R oligomers (Fuxe et al., 2003). Moreover, the metabotropic glutamate 
receptors 5 (mGluR5s) are co-localized in the same GABAergic striatal output neurons and 
in glutamatergic nerve terminals in the striatum, and they form heteromeric complexes with 
A2ARs (Ferré et al., 2002; Rodrigues et al., 2005). This co-localization provides a 
morphological framework for the existence of multiple mGlu5/A2A/D2 receptor interactions 
(Cabello et al., 2009). Thus, it is proposed that the increase in glutamate and adenosine 
extracellular levels activates A2AR and mGluR5, both synergizing and promoting the 
inhibition of D2Rs (Ferré et al., 2007).  
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Of note is the characterization of A1R-A2AR heteromers with antagonistic activities between 
the two receptors, preferentially at presynaptically level in glutamatergic terminals of 
cortico-striatal afferents to the MSNs (Ciruela et al., 2006; Quiroz et al., 2009). Under baseline 
conditions, reduced levels of extracellular adenosine stimulate the activity of A1Rs while 
glutamatergic neurotransmission is inhibited. Under conditions of neuronal excitability, the 
extracellular adenosine levels are increased, showing A2ARs affinity and inhibiting A1R 
activity, and promoting the release of glutamate, which in turn also increases activation of 
mGluR5 synergizing with A2ARs and thereby facilitating more glutamate release (Rodrigues 
et al., 2005).  
Interestingly, striatal A2ARs expression levels have been found to be increased in PD patients 
with dyskinesias; this upregulation is attributed to the effect of levodopa (L-dopa) treatment 
(Calon et al., 2004). Recently, it has been proven that high A2ARs levels in the striatum and in 
lymphocytes correlate with motor symptoms in PD patients who were previously either not 
pharmacologically treated or were treated with a wide spectrum of drugs and not restricted 
to only L-dopa (Varani et al., 2010). Therefore, A2AR upregulation in PD, which tonically 
inhibits D2R (see above), together with the low dopamine content in the striatum, a 
consequence of the death of dopaminergic neurons from the substantia nigra, contribute to a 
synergistic impairment of D2R function. 
It remains to be clarified whether upregulation of A2ARs levels in PD is a hallmark of the 
disease or is a consequence of dopaminergic terminal drop-off in the striatum. This issue has 
been quite controversial, as increased striatal levels of A2ARs were shown in 6-
hydroxidopamine (6-OHDA)-treated rats, as a consequence of dopamine denervation (Pinna 
et al., 2002), and also in 6-OHDA-treated rats with intermittent L-dopa treatment 
(Tomiyama et al., 2004).  
3. Clinical trials with A2AR antagonists in PD 
L-dopa remains the most effective treatment for symptomatic relief of PD, although its 
pharmacological administration over time induces motor dysfunctions such as dyskinesias 
(Obeso et al., 2000). One of the strategies to reduce these is the administration of  
non-dopaminergic drugs that modulate dopaminergic neurotransmission. Indeed, A2AR has 
emerged as a potential pharmacological target in PD, as its relationship with the 
dopaminergic system has been clearly demonstrated (Ferré et al., 2002). There have been 
several clinical trials with A2AR antagonists, such as istradefylline (also known as KW-6002), 
confirming that their administration to PD patients reduces the “OFF” time and dyskinesias 
induced by L-dopa treatment (Bara-Jimenez et al., 2003; Factor et al., 2010; Hauser et al., 
2003, 2008; LeWitt et al., 2008b; Mizuno et al., 2010; Stacy et al., 2008). As A2ARs expression 
levels are nearly exclusive of the striatum, the use of specific antagonists for these receptors 
could promote a specific brain-area effect (Brooks et al., 2008). Interestingly, it has recently 
been described how KW-6002 preferentially targets the A2AR within the postsynaptic 
A2AR/D2R oligomer located at the MSNs, thus potentiating D2R-mediated motor activation 
(Orru et al., 2011). Therefore, although the use of istradefylline as a monotheraphy in PD has 
not been statistically demonstrated (Fernandez et al., 2010), its administration as a 
coadjuvant seems to allow a reduction in the L-dopa dose.  
As mentioned before, there are heteromers formed by A2AR, D2R and mGluR5 in striatal 
GABAergic neurons or MSNs (Cabello et al., 2009). It is proposed that the increase in 
glutamate and adenosine extracellular levels activates A2AR and mGluR5, both synergizing 
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and promoting the inhibition of D2Rs (Ferré et al., 2007). Interestingly, it has been 
demonstrated in a rat model of PD that the simultaneous inhibition of A2AR and mGluR5 
synergistically reverses the parkinsonian deficits in these animals (Coccurello et al., 2004). In 
this line, the use of mGluR type I antagonists as a therapy for PD has been proposed (Bonsi 
et al., 2007). Overall, this explains why pharmaceutical companies are going after either 
single compounds or combinations of drugs that will simultaneously antagonize A2AR and 
mGluR5. 
4. Brain DNA methylation 
Studies in mice deficient in enzymes that control DNA methylation and the results of folate-
free diets have established an important role for methylation in the development of the 
nervous system (Waterland & Jirtle, 2003). In fact, the manipulation of methylation and 
acetylation affects neuronal vulnerability in experimental models of neurodegenerative 
diseases (El-Maarri, 2003). It has also been proposed that memory processes are highly 
related with the level of neuronal methylation (Day & Sweatt, 2010; Liu et al., 2009).  
DNA methylation is a normal process that occurs during mammal embryo development, 
and it is also implicated in X-chromosome inactivation and repression of proviral genes and 
endogenous transposons. This chemical modification is one of the most important 
epigenetic mechanisms in gene silencing in mammals. It is characterized by the methylation 
of cytosines that precede guanines in the well-known CpG sites. Those genome CpG-rich 
regions are called CpG islands (CGIs); they present a size between 200 bp and several 
kilobases. In general, these active gene promoter regions are not methylated, while the 
inactive gene promoter regions are fully methylated. Most CGIs are found in 5' UTR regions 
and in the first exon, although they can be found in regions distal to the transcription start 
site and in intronic regions. In normal tissues, CGIs are usually non-methylated, while they 
are methylated in tumorous cells, especially in tumor repressor genes (Illingworth & Bird, 
2009; Jones, 1999).  
Methylation of CpG sites is achieved by the action of DNA metyltransferases (Dnmt) which 
catalyze the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to DNA. The 
human DNA Methylome map has recently been published, annotating those genes found 
methylated in normal tissues and in human diseases such as Alzheimer’s disease (AD) and 
schizophrenia (SZ) (Ballestar & Esteller, 2008). DNA methylation in the CpG sites interferes 
with gene expression in two ways. The first is interference with the binding of transcription 
factors to DNA through the methyl group. The second is caused by the binding of specific 
proteins, such as MeCP2, MBD1 and MBD2, to methyl CpG sites (methyl-CpG-binding 
proteins, MBDs). These MBDs recruit histone-modifying and chromatin-remodeling 
complexes to methylated sites (Portela & Esteller, 2010). The importance of these proteins is 
demonstrated by Rett syndrome, a disease causing severe mental dysfunction and brought 
on by MeCP2 mutations (Amir et al., 1999).  
The role of DNA methylation in the brain is an emerging field of research. Neuronal DNA 
methylation is modified with lifespan, and the analysis of 12 loci related with AD has 
revealed an age-specific epigenetic drift in the percentage of DNA methylation (Siegmund et 
al. 2007; Wang et al., 2008). Moreover, the degree of gene methylation varies among the 
different cerebral regions, and it has been reported that DNA methyltransferase 1 (Dnmt1) 
expression levels are different in the various cerebral regions (Ladd-Acosta et al., 2007). 
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Interestingly, Dnmt 1 is increased in the cortical interneurons where the GAD67 gene is 
suppressed in SZ patients (Veldic et al., 2004, 2005). 
Finally, epigenetic therapies such as the use of demethylating agents are widely established 
in the treatment of tumors (Herranz & Esteller, 2006), but their use in neurodegeneration is 
poorly studied. In this line, S-adenosylmethionine (SAM) is a methyl group donor molecule 
necessary for DNA methylation which is reduced in AD (Linnebank et al., 2010; Morrison et 
al., 1996). There have been proposals to use it as a therapy for AD (Scarpa et al., 2003). Its 
administration to cell lines down-regulates PSEN1 and reduces -amyloid production. In 
contrast, deprivation of SAM up-regulates PSEN1, increasing -amyloid deposits in APP 
transgenic mice (Fuso et al., 2005, 2008). Interestingly, mice treated with L-methionine 
downregulate GAD67 and reelin levels by increasing DNA methylation of their respective 
gene promoter regions (Tremolizzo et al., 2002).  
5. Endogenous SAM biosynthesis cycle and alterations in PD 
SAM is the main biological methyl donor molecule in the methionine metabolic cycle, which 
is involved in the methylation of DNA, and protein, lipid and polyamine synthesis. 
Moreover, it is a precursor of glutathione in the liver and also perhaps in the brain 
(Vitvitsky et al, 2006). When SAM is demethylated, it is transformed into S-
adenosylhomocysteine (SAH) which in turn is hydrolysed into homocysteine (HCY) and 
adenosine. To prevent the accumulation of HCY, it is remethylated to form methionine 
(Chiang et al., 1996; Lu, 2000) (see Figure 1). The SAM/SAH ratio is also known as 
methylation potential and its endogenous maintenance is very important. 
L-dopa is the conventional drug used in the treatment of PD to minimize the lack of 
endogenous dopamine in these patients (Lewitt, 2008a; Tolosa et al., 1998). However, 
chronic treatment with L-dopa has been associated with hyperhomocysteinemia in plasma, 
peripheral tissues and brain of PD patients, as L-dopa metabolism requires S-
adenosylmethionine (SAM) as a methyl donor (Lu, 2000; Müller et al., 2009a; Nutt, 2008; 
O’Suilleabhain et al, 2004; Zoccolella et al., 2006, 2009, 2010). Interestingly, it has been shown 
that L-dopa treatment in mice depletes the brain SAM content (Liu et al., 2000). In addition, 
elevated plasma homocysteine (Hcy) levels have been related to cognitive and motor 
impairment and have also been associated with the pathogenesis of other neurological 
diseases such as stroke and AD (Morris, 2003; Quadri et al., 2004; Seshadri et al., 2002). 
Interestingly, some polymorphisms described in MTHFR gene (methylenetetrahydrofolate 
reductase) have been associated with a reduction in its enzymatic activity, promoting an 
increase in the Hcy levels in L-dopa-treated PD patients (Frosst et al., 1995; Yasui et al., 
2000). Vitamin B6 enhances the direct flow of Hcy to cysteine, the precursor of gutathione. 
Deficits in vitamin B6 induce oxidative stress and, in turn, enhance Hcy (Obeid et al., 2009). 
Therefore, several factors have been related with hyperhomocysteinemia and a concomitant 
reduction in the SAM levels in blood and cerebrospinal fluid of L-dopa-treated PD patients 
(Cheng et al., 1997). These include the following: 1. An excessive production of S-
adenosylhomocysteine (SAH) when L-dopa is metabolized by catechol-O-methyltransferase 
(COMT), depleting the SAM levels an in turn decreasing the SAM/SAH ratio; 2. Reduced 
MTHFR enzymatic activity; and 3. Vitamin B12 or folic acid deficits (Dos Santos et al., 2009; 
Miller et al., 2003; Müller et al., 2001, 2009b; Woitalla et al., 2004). In this context, some 
clinical trials have been carried out using decarboxylase and COMT inhibitors (for instance, 
carbidopa and entacapone/tolcapone, respectively) or vitamin B12 and folate 
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supplementation to reduce Hcy levels in PD patients (Müller et al., 2003, 2006; Zoccolella et 
al., 2007). 
 
 
Fig. 1. SAM biosynthesis cycle 
6. Epigenetic study of ADORA2A 
A2AR gene (ADORA2A) is localized to chromosome 22 (Le et al., 1996; MacCollin et al., 1994; 
Peterfreund et al., 1996). It consists of two coding exons (exon 2 and 3) separated by a single 
intron of nearly 7 Kb. The exon 1 is a non-coding exon which is located at 5′ upstream exon 2 
and presents 6 tissue-specific isoforms: h1A-h1F (Yu et al., 2004) (Figure 2A). Interestingly, 
differential expression of these isoforms has been reported in granulocytes of patients 
suffering from sepsis, indicating that 5′ UTR plays an important regulatory role in A2AR 
expression (Kreth et al., 2008). We recently identified a functional CGI surrounding the h1E 
isoform, demonstrating that DNA methylation controls basal ADORA2A expression in 
several cell lines and that it is one of the molecular mechanisms responsible for A2ARs’ 
differential expression levels in specific human brain areas, such as the putamen and the 
cerebellum (Buira et al., 2010a, 2010b). Interestingly, we showed that A2AR expression levels 
can be modulated by SAM treatment in SH-SY5Y (human neuroblastoma) and U87MG 
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(human glioblastoma) cell lines. In this context, A2ARs levels have been reported to be 
upregulated in PD patients (Calon et al., 2004; Varani et al., 2010). Therefore, we postulated 
that SAM treatment could represent a therapeutical tool to reduce A2ARs levels in these 
patients. This is based on the fact that the DNA methylation profile of striatal ADORA2A in 
PD patients is lower than the one found in SH-SY5Y and U87MG cells (Figure 2B). 
Therefore, as A2ARs cell surface levels are reduced in these cells after SAM treatment, due to 
an increase in the DNA methylation profile of ADORA2A (Buira et al., 2010a), it is also 
plausible that the same mechanism of action could play a role in the striatum of PD patients. 
  
 
Fig. 2. A, Scaled representation of 5’ UTR region of human ADORA2A gene, containing 6 
isoforms of non-coding exon 1 (1A-1F). Two CGIs surrounding exon 1E were recently 
described (Buira et al., 2010b). The translational start site (ATG) is indicated with an arrow. 
B, DNA methylation percentage (mean ± SD) of a locus located in the CGIs of exon 1E of 8 
human post-mortem putamens of PD (black bars) and in two cell lines (black line, SH-SY5Y, 
n=3; dotted lines, U87-MG, n=3). 
7. Clinical trials with SAM 
SAM has been widely used for the treatment of liver diseases, as it increases the glutathione 
content (Friedel et al. 1989). Interestingly, SAM has antidepressant properties and its long 
term tolerability is excellent, presenting few side effects (Bell et al., 1988; Bottiglieri & 
Hyland, 1994; Delle Chiaie et al., 2002; Kagan et al., 1990; Lipinski et al., 1984; Papakostas, 
2009, 2010). Moreover, SAM administration in patients with depression and dementia, 
intravenously or orally, has shown that it crosses the blood-brain barrier, and as a result, it is 
detected at increased levels in the cerebrospinal fluid (Bottiglieri et al., 1990). 
Impaired transmethylation potential in L-dopa-treated PD patients has been proposed (De 
Bonis et al., 2010). The authors argue that a possible global DNA hypomethylation in 
hyperhomocysteinemic PD patients could be responsible for a generalized gene expression 
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dysregulation and for playing a role in the outcome of the pathology. In accordance with 
this, another study has shown improved cognitive function in PD patients with a higher 
SAM/SAH ratio and higher plasma vitamin B6 (Obeid et al., 2009). It is noteworthy that 
SAM treatment improved depression of PD patients in an open-label clinical trial (Di Rocco 
et al., 2000). In fact, vitamin dietary supplementation, including SAM, has been shown to be 
effective in patients with early and moderate stages of AD (Chan et al., 2008; Panza et al., 
2009; Remington et al., 2009; Shea and Chan, 2008). Moreover, SAM supplementation also 
presented antioxidant properties in an AD animal model (Cavallaro et al., 2010). In line with 
this, oxidative stress is also present in early-stages of PD (Ferrer et al., 2010), which points 
up the benefits of SAM administration in this pathology as an adjunctive treatment. 
8. Conclusions and proposals for future PD interventions 
As mentioned in the introduction, it is noteworthy that inactivation of A2ARs enhances the 
affinity of D2Rs for dopamine, this being the probable mechanism underlying the 
prodopaminergic effect of A2ARs antagonists in several clinical trials with PD patients. In 
this chapter, we have examined the literature which, in combination with our studies based 
on ADORA2A transcriptional regulation, has led us to propose SAM treatment as an 
epigenetic tool to modulate the increased expression of A2ARs in PD. 
It is obvious that SAM treatment presents a broad spectrum of gene targets, and not only 
tumor supressor genes. However, it has been reported that SAM treatment promotes a 
decrease in the growth of hepatocellular carcinoma cells and liver cancer in animal models, 
hypothesising the methylation and repression of oncogenic gene promoters by this drug 
(Cai et al., 1998; Pascale et al., 1992). However, the existence of several clinical trials with 
SAM and the reduced number of side-effects in its administration must be taken into 
account. Based on our studies, and bearing in mind the restrictive expression of A2ARs in the 
brain (mainly in 95% of striatal neurons), we postulate that SAM treatment would have a 
“specific” effect on A2ARs in the brain. This would be especially true in a cerebral region 
where it colocalizes with D2Rs, which in turn present reduced activity due to the low 
dopamine content in PD. Then, although SAM treatment would reduce the expression of 
hypomethylated genes, its effect on A2ARs might represent significant activation of D2Rs. 
Thus, the possible beneficial role of SAM in these patients should be examined in 
randomized controlled studies, examining supplementation to L-dopa (allowing a reduction 
of its dose) and to A2ARs antagonists (such as istradefylline), or in triple administration with 
both current therapies. 
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